Biotech Stocks to Watch: Up to 46.34% Return in 1 Month

Biotech Stocks to Watch

This Biotech Stocks forecast is designed for investors and analysts who need predictions of the best performing stocks for the whole Biotechnology Industry (See Industry Package). It includes 20 stocks with bullish and bearish signals and indicates the best biotech stocks to buy:

  • Top 10 biotech stocks for the long position
  • Top 10 biotech stocks for the short position

Package Name: Industry Package – Biotech Stocks
Forecast Length: 1 Month (6/26/15 – 7/26/15)
I Know First Average: 4.04% (Long) and 5.92% (Short)

Biotech Stocks To Watch

 In the recent 07/26/2015 forecast that was part of the Biotech package, 12 of the 20 stocks between the long and short positions increased in accordance with the algorithm’s prediction. The top performing stock for the long position was EXEL with a spectacular return of 46.34%, while KITE also had noteworthy returns of 12.09%. For the short position, the stock that decreased the most was BIIB with a loss of 27.05%, while MACK also posted significant losses of 20.58% as the algorithm predicted. The average returns for the long and short positions were 4.04% and 5.92% Respectively, both of which beat the S&P by at least 4.5% over the same time period

Exelixis (EXEL) is a Biotech company concerned with developing small molecule therapies with the potential to improve the treatment of cancer, and moving these treatments to market. Its signature product is Cometriq, which became FDA approved in 2011, 17 years after the company went public. EXEL achieved success with their late stage trial of a new treatment for kidney cancer called METEOR. Additionally, news surfaced that Exel’s Cometriq drug continues to exceed sales, a big relief for the company considering the fact that Cometriq is a thyroid cancer treatment, and thyroid cancer is not incredibly prevalent. In the same spate of studies undertaken by Exelixis in recent months, it became apparent that Cometriq could also be used as a Kidney treatment, which bolsters Exelixis’ prospects as a cash flow generating firm.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First algorithmic traders.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.